Copeptin: a neuroendocrine biomarker of COVID-19 severity.

Biomark Med

Orthopedic Surgery Department, Dean of Faculty of Medicine (Girls), Al-Azhar University, Cairo, 11884, Egypt.

Published: June 2022

To investigate the change in a serum level of copeptin, a neuroendocrine biomarker, in differentiating grades of COVID-19 severity on admission time and to find its diagnostic potential. 160 COVID-19 patients were classified according to disease severity into 80 mild to moderate and 80 severe patients. Serum copeptin level was assessed by ELISA on their admission time. Besides, serum CRP, ferritin and D-dimer were estimated. Severe COVID-19 patients showed higher serum copeptin level in comparison to mild to moderate cases, with diagnostic potential to distinguish disease severity with 93.33% sensitivity and 100% specificity at cutoff value >18.5 Pmol/l. Serum copeptin was remarkably increased with COVID-19 severity with reasonable differentiation potential for recently admitted patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966690PMC
http://dx.doi.org/10.2217/bmm-2021-1100DOI Listing

Publication Analysis

Top Keywords

covid-19 severity
12
serum copeptin
12
copeptin neuroendocrine
8
neuroendocrine biomarker
8
admission time
8
diagnostic potential
8
covid-19 patients
8
disease severity
8
mild moderate
8
copeptin level
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!